Shree Ishita Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.25 M
as on 01-01-2025
- Paid Up Capital ₹ 0.10 M
as on 01-01-2025
- Company Age 38 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Revenue -42.19%
(FY 2016)
- Profit 3.82%
(FY 2016)
- Ebitda -44.82%
(FY 2016)
- Net Worth
- Total Assets -1.12%
(FY 2016)
About Shree Ishita Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.25 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Nagendra Agrawal, Kanta Agrawal, and Ivanshu Agrawal serve as directors at the Company.
- CIN/LLPIN
U24231GJ1986PTC008596
- Company No.
008596
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
02 Apr 1986
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Shree Ishita Pharmaceuticals Private Limited offer?
Shree Ishita Pharmaceuticals Private Limited offers a wide range of products and services, including Hand Sanitizers & Personal Hygiene, Beauty Soap, Common Disease Medicines, Pharmaceutical Medicine, Allopathic Medicines, Pharmaceutical Syrup, Dry Syrups, Herbal Soaps, Neem Soap.
Who are the key members and board of directors at Shree Ishita Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ivanshu Agrawal  | Director | 23-Mar-2016 | Current |
| Nagendra Agrawal | Director | 02-Apr-1986 | Current |
| Kanta Agrawal | Director | 02-Apr-1986 | Current |
Financial Performance of Shree Ishita Pharmaceuticals.
Shree Ishita Pharmaceuticals Private Limited, for the financial year ended 2016, experienced significant reduction in revenue, with a 42.19% decrease. The company also saw a slight improvement in profitability, with a 3.82% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth | |||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Shree Ishita Pharmaceuticals?
In 2017, Shree Ishita Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Shree Ishita Pharmaceuticals?
Unlock and access historical data on people associated with Shree Ishita Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Shree Ishita Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Shree Ishita Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
